Heterologous expression, purification, and characterization of cytochrome P450sca-2 and mutants with improved solubility in Escherichia coli

Protein Expression and Purification

Volumn 65, Issue 2, 2009, Pages 196-203

  Li, Pan ^a   Guan, Hong ^a   Li, Jin ^a   Lin, Zhanglin ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

Cytochrome P450sca 2; Directed evolution; E. coli; GFP; Recombinant expression; Solubility

Indexed keywords

CYTOCHROME P450; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; MUTANT PROTEIN;

ARTICLE; BIOSYNTHESIS; CHEMISTRY; ENZYMOLOGY; ESCHERICHIA COLI; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MUTATION; POLYMERASE CHAIN REACTION; SOLUBILITY; STREPTOMYCES;

CYTOCHROME P-450 ENZYME SYSTEM; ESCHERICHIA COLI; GREEN FLUORESCENT PROTEINS; MUTANT PROTEINS; MUTATION; POLYMERASE CHAIN REACTION; RECOMBINANT FUSION PROTEINS; SOLUBILITY; STREPTOMYCES;

ESCHERICHIA COLI; STREPTOMYCES; STREPTOMYCES CARBOPHILUS;

EID: 61749090940     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2008.11.012     Document Type: Article

References (46)

1. Serizawa N., Nakagawa K., Hamano K., Tsujita Y., Terahara A., and Kuwano H. Microbial hydroxylation of ML-236B (compactin) and monacolin K (MB-530B). J. Antibiot. 36 (1983) 604-607
2. Serizawa N., Serizawa S., Nakagawa K., Furuya K., Okazaki T., and Terahara A. Microbial hydroxylation of ML-236B (compactin) studies on microorganisms capable of 3β-hydroxylation of ML-236B. J. Antibiot. 36 (1983) 887-891
3. Tsujita Y., Kuroda M., Shimada Y., Tanzawa K., Arai M., Kaneko I., Tanaka M., Masuda H., Tarumi C., Watanabe Y., and Fujii S. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim. Biophys. Acta 877 (1986) 50-60
4. Koga T., Shimada Y., Kuroda M., Tsujita Y., Hasegawa K., and Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim. Biophys. Acta 1045 (1990) 115-120
5. T. Matsuoka, S. Miyakoshi, Pure cytochrome P-450 enzymes are obtained from Streptomyces carbophilus and used for hydroxylation especially of macrolide antibiotics, US Patent 5179013A, 1988.
6. Matsuoka T., Miyakoshi S., Tanzawa K., Nakahara K., Hosobuchi M., and Serizawa N. Purification and characterization of cytochrome P-450sca from Streptomyces carbophilus. Eur. J. Biochem. 184 (1989) 707-713
7. Serizawa N., and Matsuoka T. A two component-type cytochrome-P-450 monooxygenase system in a prokaryote that catalyzes hydroxylation of ML-236B to pravastatin, a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase. Biochim. Biophys. Acta 1084 (1991) 35-40
8. Watanabe I., Nara F., and Serizawa N. Cloning, characterization and expression of the gene encoding cytochrome P-450(Sca-2) from Streptomyces carbophilus involved in production of pravastatin, a specific HMG-CoA reductase inhibitor. Gene 163 (1995) 81-85
9. Hosobuchi M., Kurosawa K., and Yoshikawa H. Application of computer on monitoring and control of fermentation process: microbial conversion of ML-236B sodium to pravastatin. Biotechnol. Bioeng. 42 (1993) 815-820
10. Peng Y.L., and Demain A.L. Bioconversion of compactin to pravastatin by Actinomadura sp. ATCC 55678. J. Mol. Catal. B: Enzym. 10 (2000) 151-156
11. Park J.W., Lee J.K., Kwon T.J., Yi D.H., Kim Y.J., Moon S.H., Suh H.H., Kang S.M., and Park Y.I. Bioconversion of compactin into pravastatin by Streptomyces sp. Biotechnol. Lett. 25 (2003) 1827-1831
12. Chen C.H., Hu H.Y., Cho Y.C., and Hsu W.H. Screening of compactin-resistant microorganisms capable of converting compactin to pravastatin. Curr. Microbiol. 53 (2006) 108-112
13. Katz E., Thompson C.J., and Hopwood D.A. Cloning and expression of the tyrosinase gene from Streptomyces antibioticus in Streptomyces lividans. J. Gen. Microbiol. 129 (1983) 2703-2714
14. A. Arisawa, A. Kumeda, Expression system of actinomycete-origin cytochrome P450 in Escherichia coli, European Patent 1500704A1, 2005.
15. Waldo G.S. Genetic screens and directed evolution for protein solubility. Curr. Opin. Chem. Biol. 7 (2003) 33-38
16. Roodveldt C., Aharoni A., and Tawfik D.S. Directed evolution of proteins for heterologous expression and stability. Curr. Opin. Struct. Biol. 15 (2005) 50-56
17. Hoover D.M., and Lubkowski J. DNAWorks: an automated method for designing oligonucleotides for PCR-based gene synthesis. Nucleic Acids Res. 30 (2002) e43
18. Gill S.C., and von Hippel P.H. Calculation of protein extinction coefficients from amino-acid sequence data. Anal. Biochem. 182 (1989) 319-326
19. Omura T., and Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239 (1964) 2370-2378
20. Otey C.R. High-throughput carbon monoxide binding assay for cytochrome P450. In: Arnold F.H., and Georgiou G. (Eds). Methods Mol. Biol. vol. 230 (2003), Humana Press Inc., Totowa 137-139
21. Schenkman J.B., and Jansson I. Spectral analyses of cytochrome P450. In: Phillips I.R., and Shephard E.A. (Eds). Methods Mol. Biol. vol. 320 (2006), Humana Press Inc., Totowa 11-18
22. Z.L. Lin, S. Li, Y. Chen, Identification of viral peptide fragments for vaccine development, in: B.W. Hicks (Ed.), Methods Mol. Biol., vol. 515, Humana Press Inc., Totowa, 2009.
23. Joo H., Lin Z.L., and Arnold F.H. Laboratory evolution of peroxide-mediated cytochrome P450 hydroxylation. Nature 399 (1999) 670-673
24. Stemmer W.P.C. Rapid evolution of a protein in vitro by DNA shuffling. Nature 370 (1994) 389-391
25. Minagawa H., and Kaneko H. Effect of double mutation on thermostability of lactate oxidase. Biotechnol. Lett. 22 (2000) 1131-1133
26. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., and Pease L.R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77 (1989) 51-59
27. Peitsch M. Protein modeling by E-mail. Bio/Technology 13 (1995) 658-660
28. Guex N., and Peitsch M.C. Swiss-Model and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18 (1997) 2714-2723
29. Schwede T., Kopp J., Guex N., and Peitsch M.C. Swiss-Model: an automated protein homology-modeling server. Nucleic Acids Res. 31 (2003) 3381-3385
30. Kopp J., and Schwede T. The Swiss-Model repository of annotated three-dimensional protein structure homology models. Nucleic Acids Res. 32 (2004) D230-D234
31. Arnold K., Bordoli L., Kopp J., and Schwede T. The Swiss-Model workspace: a web-based environment for protein structure homology modeling. Bioinformatics 22 (2006) 195-201
32. Yasutake Y., Imoto N., Fujii Y., Fujii T., Arisawa A., and Tamura T. Crystal structure of cytochrome P450 MoxA from Nonomuraea recticatena (CYP105). Biochem. Biophys. Res. Commun. 361 (2007) 876-882
33. Laskowski R.A., MacArthur M.W., Moss D.S., and Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26 (1993) 283-291
34. Hussain H.A., and Ward J.M. Enhanced heterologous expression of two Streptomyces griseolus cytochrome P450s and Streptomyces coelicolor ferredoxin reductase as potentially efficient hydroxylation catalysts. Appl. Environ. Microbiol. 69 (2003) 373-382
35. Celik A., Flitsch S.L., and Turner N.J. Efficient terpene hydroxylation catalysts based upon P450 enzymes derived from Actinomycetes. Org. Biomol. Chem. 3 (2005) 2930-2934
36. Barnes H.J. Maximizing expression of eukaryotic cytochrome P450s in Escherichia coli. In: Johnson E.F., and Waterman M.R. (Eds). Methods Enzymol. vol. 272 (1996), Academic Press Inc., San Diego 3-14
37. Schwaneberg U., Dannert C.S., Schimitt J., and Schmid R.D. A continuous spectrophotometric assay for P450 BM-3, a fatty acid hydroxylating enzyme, and its mutant F87A. Anal. Biochem. 269 (1999) 359-366
38. Glieder A., and Meinhold P. High-throughput screens based on NAD(P)H depletion. In: Arnold F.H., and Georgiou G. (Eds). Methods Mol. Biol. vol. 230 (2003), Humana Press Inc., Totowa 157-170
39. Waldo G.S., Standish B.M., Berendzen J., and Terwilliger T.C. Rapid protein-folding assay using green fluorescent protein. Nat. Biotechnol. 17 (1999) 691-695
40. Pedelacq J.D., Piltch E., Liong E.C., Berendzen J., Kim C.Y., Rho B.S., Park M.S., Terwilliger T.C., and Waldo G.S. Engineering soluble proteins for structural genomics. Nat. Biotechnol. 20 (2002) 927-932
41. Sørensen H.P., and Mortensen K.K. Soluble expression of recombinant proteins in the cytoplasm of Escherichia coli. Microb. Cell Fact. 4 (2005) 1-8
42. Zhao H., Moore J.C., Volkov A.A., and Arnold F.H. Methods for optimizing industrial enzymes by directed evolution. In: Demain A.L., and Davies J.E. (Eds). Manual of Industrial Microbiology and Biotechnology (1999), American Society for Microbiology (ASM), Washington, DC
43. Jiang S.M., Li C.H., Zhang W.W., Cai Y.H., Yang Y.L., Yang S., and Jiang W.H. Directed evolution and structural analysis of N-carbamoyl-d-amino acid amidohydrolase provide insights into recombinant protein solubility in Escherichia coli. Biochem. J. 402 (2007) 429-437
44. W.L. DeLano, The PyMOL Molecular Graphics System, 2002, Available from: .
45. Ito S., Hata T., Watanabe I., Matsuoka T., and Serizawa N. Crystal structure of cytochrome P450sca from Streptomyces carbophilus involved in production of pravastatin, a cholesterol-lowering drug. FASEB J. 11 (1997) A776
46. Ito S., Matsuoka T., Watanabe I., Kagasaki T., Serizawa N., and Hata T. Crystallization and preliminary X-ray diffraction analysis of cytochrome P450(sca-2) from Streptomyces carbophilus involved in production of pravastatin sodium, a tissue-selective inhibitor of HMG-CoA reductase. Acta Crystallogr. D Biol. Crystallogr. 55 (1999) 1209-1211